Cart (0 Items)
Your cart is currently empty.
View ProductsSize | 100ug, 1MG |
---|---|
Isotype | IgG1, kappa |
Brand | ProteoGenix |
Product type | Primary Antibodies |
Clonality | Monoclonal Antibody |
Expression system | Mammalian cells |
Applications | Elisa, WB |
Product name | Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb - Research Grade |
---|---|
Source | CAS 1363687-32-4 |
Species | Chimeric |
Expression system | Mammalian cells |
Molecular weight | 145kDa |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Aliases /Synonyms | Dinutuximab,14.18,MAb-14.18,MOAB Ch14.18,ganglioside GD2,anti-ganglioside GD2 |
Reference | PX-TA1323 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Dinutuximab is ahuman/mouse chimeric monoclonal antibody of isotype IgG1 that targets GD2. GD2 is a disialoganglioside expressed on neuroectodermal tumors, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. By binding to GD2, dinutiximab induces apoptosis and inhibits the proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), to treat childrens with high-risk neuroblastoma.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.